Bridgebio Oncology Therapeutics Says BBO-8520 Monotherapy Shows 63% ORR, 100% DCR In 2L+ KRASG12C NSCLC; BBO-11818 And BBO-10203 Monotherapy Data Update Expected In Q4 2026; Expanded BBO-8520 Plus Pembrolizumab Dataset Expected In Mid-2027; BBO-11818 And BBO-10203 Combination Data In CRC And PDAC Expected Mid-2027